Australian Dementia Forum 2021

31 May – 1 June

Virtual Handbook

Australian
Dementia Network
REGISTRY. CLINICS. TRIALS.

www.adf2021.org.au

adf2021@eventstudio.com.au

Australian Dementia Network
REGISTRY. CLINICS. TRIALS.

Use the conference social media handles to share your comments, feedback, experience of the conference.

🐦 https://twitter.com/ADF2021   f https://www.facebook.com/ADF2021/

The Australian Dementia Network

Dementia is a major and growing health issue for Australians. In 2020, an estimated 459,000 people are living with dementia and this number is growing by about 250 persons each day.

Dementia is the second leading cause of death of Australians and is the single greatest cause of disability in Australians aged 65 and over. It is estimated to cost the nation more than $15 billion annually.

The Australian Dementia Network (ADNeT) brings together Australia's leading scientists, researchers, and clinicians into the largest national network of experts in Alzheimer's disease and other forms of dementia.
Through our research, we strive to improve the quality of clinical care for people with dementia and mild cognitive impairment and accelerate the development of new therapies.

Our initiatives

Our work is organised around three key initiatives that interact to deliver value and tangible benefits for people living with dementia and their care partners.

The Australian Dementia Network Screening and Trials Program – Cutting-edge specialist diagnostics

The Australian Dementia Network Screening and Trials initiative is creating opportunities for Australians living with dementia to access new therapies under development by facilitating recruitment into clinical trials across Australia. It provides clinicians with cutting-edge specialist diagnostic techniques for eligible patients free of cost.

For more information:

To refer your patient to our program, contact **ADNET-screening@unimelb.edu.au**

Interested individuals can register to participate in clinical trials – see **https://www.australiandementianetwork.org.au/i-am-a-member-of-the-public-or-consumer/volunteer-for-trials/**

For more information, contact Dr Jo Robertson, our national ADNeT Screening and Trials coordinator, on **jo.robertson@unimelb.edu.au** or **0408 508 121**.

The Australian Dementia Network Registry – A Clinical Quality Registry to drive continuous quality improvement in clinical care

The Australian Dementia Network Registry is a clinical quality registry for people newly diagnosed with either dementia or mild cognitive impairment. It collects data about the diagnosis, clinical care and outcomes of this population.

For more information:

If your organisation is interested in participating in the Registry or you would like more information, contact **adnet.registry@monash.edu** or **1800 314 421**.

The Australian Dementia Network Memory Clinic Initiative - harmonising the diagnostic standards of memory clinics

The Australia Dementia Network Memory Clinics initiative is working to harmonise the diagnostic standards of memory clinics across Australia and develop training, professional development, and easily accessible clinical resources for health professional staff.

For more information:

To list your clinic on our national list, available online, please email **adnet.mc@unsw.edu.au**

Bi-monthly webinars - Watch past webinars on our YouTube channel or register via our website or our social media channels.

Or contact us at **Adnet.mc@unsw.edu.au** for more information.

Stay in touch

🐦 @ADNeT_Australia

✉ adnet-info@unimelb.edu.au

📞 +61 3 9035 9635

www.australiandementianetwork.org.au

Australian Dementia Network
Faculty of Medicine, Dentistry and Health Sciences
Level 2, Alan Gilbert Building
The University of Melbourne
Victoria 3010 Australia

LISTEN TO WHAT THE
FUTURE HAS TO SAY IN
ALZHEIMER'S DISEASE

Join the new conversation with leaders, influencers, innovators
and brilliant minds about the future of Alzheimer's disease.

ADBioHub.com.au

Biogen.

CSIRO | Australian eHealth Research Centre

Powering digital transformation in ageing and dementia

The Australian e-Health Research Centre (AEHRC) is CSIRO's digital
health research program – enabling the digital transformation of
healthcare to improve services and clinical treatment for Australians.

The AEHRC works with collaborators across the healthcare system to improve diagnosis and
treatment. In aged care, the AEHRC brings our expertise in biomedical imaging and genomics,
to enable early precision healthcare in diagnosis and treatment, while our health service
research develops technologies that support services for those living with dementia.

csiro.au/adnet

Australia's National Science Agency

Sponsors

Platinum Sponsor

About NHMRC

NHMRC has been supporting health and medical research and advancing health and medical knowledge to improve the health of all Australians since 1937. NHMRC's mission is building a healthy Australia.

As the Australian Government's lead agency for funding health and medical research, NHMRC invests in the creation of knowledge about the mechanisms underlying health and disease and in the development of better ways to prevent and treat ill health. We support the translation of evidence from research into public health policy and clinical practice, and we promote the highest standards of research ethics and integrity.

We fund research across the spectrum from discovery to implementation science. We balance the needs of the community, government and the research sector, supporting both investigator-initiated and priority-driven research. We understand the important contribution that health and medical research makes to creating knowledge and improving lives.

NHMRC is proud to support the 2021 Australian Dementia Forum (ADF 2021). The NHMRC National Institute for Dementia Research (NNIDR), delivered in partnership with Dementia Australia, closed on 30 June 2020 after a successful five years supporting the Australian dementia research sector and assisting with the delivery of the Australian Government's Boosting Dementia Research Initiative (BDRI).

NHMRC remains committed to supporting dementia research. For more information, please visit the NHMRC dementia research webpage.

Gold Sponsor

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain.

For more information, please visit www.biogen.com.au or www.biogen.co.nz

Gold Sponsor

About CSIRO

CSIRO, Australia's national science agency, is committed to solving the nation's greatest health challenges through innovative science and technology. The Australian e-Health Research Centre (AEHRC) is CSIRO's digital health research program – enabling the digital transformation of healthcare to improve services and clinical treatment for Australians.

The AEHRC works with collaborators across the healthcare system to improve diagnosis and treatment. In aged care, the AEHRC brings our expertise in biomedical imaging and genomics, to enable early precision healthcare in diagnosis and treatment, while our health service research develops technologies that support services for those living with dementia.

For more information, please visit https://aehrc.com/

Virtual Sponsor

About Actinogen

Actinogen Medical is developing novel therapies for neurological diseases associated with dysregulated brain cortisol. We are currently developing the lead compound, Xanamem™, as a promising new therapy for Alzheimer's disease, Fragile X syndrome, and other neurological diseases. Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11 -HSD1 enzyme in the brain. Actinogen is planning to commence multiple phase II trials targeting improved cognition and other potential benefits.

For more information visit www.actinogen.com.au

Contents

Actinogen Medical is currently developing a drug as a promising new therapy for Alzheimer's disease, Fragile X syndrome, and other neurological diseases

There is a substantial unmet medical need

for new and improved treatments

For more information visit actinogen.com.au

Supporting Partners

Australian Dementia Network
REGISTRY. CLINICS. TRIALS.

THE UNIVERSITY of ADELAIDE

University of South Australia

Flinders UNIVERSITY

SAHMRI
South Australian Health & Medical Research Institute

Dementia Australia™

Convenor Welcome

Dear delegates,

Welcome to the Australian Dementia Forum 2021.

It is just 2 weeks short of 2 years since the previous Australian Dementia Forum was held in Tasmania, but so much has changed in that time.

COVID changed people's lives in ways that none of us could have imagined. From a conference perspective, it meant that that 2020 conference had to be cancelled and subsequent conferences were handed over to ADNeT to organise.

So, while this is the 7th Australian Dementia Forum, it is the first one under the auspices of ADNeT.

While a conference of this calibre is the result of the work of many, I would like to express my sincere thanks to:

- The Hon Greg Hunt MP, Minister for Health, for accepting our invitation to officially open the conference.

- presenters and keynote speakers, especially those who graciously accepted to participate in live Q&A sessions despite time zone differences and some very early/late starts.

- the members of the ADF organising committee, many of whom were also involved in organising the 2020 conference that got cancelled. The excellent program on offer would not have been possible without their work, suggestions, insights, and work reviewing the record number of abstracts that were submitted. The full list of members is on page 10 of this Handbook.

- the conference sponsors: NHMRC, Biogen, CSIRO and Actinogen. Their generous support of ADF2021 made this conference possible and allowed us to keep costs down and accessible for participants.

- our supporting partners: Dementia Australia, The University of Adelaide, The University of South Australia, Flinders University and SAHMRI, and the institutions that form part of ADNeT: The University of Melbourne, the University of New South Wales, Monash University, Austin Health, CSIRO, Edith Cowan University, Flinders University, The Florey, Macquarie University, NeuRA, QIMR Berghofer, SAHMRI, The University of Newcastle, The University of Queensland, The University of Sydney, and University of Tasmania, for their ongoing support.

Due to COVID, travel bans, regular outbreaks and the need to keep presenters and participants safe, we chose to run ADF2021 as a fully virtual conference. While many of us prefer the experience of face-to-face participation, we do hope that you will enjoy the conference and the many participation and networking opportunities that it offers.

This Handbook provides the **full program** in detail, as well as how to use the technology to make the most out of the conference.

I look forward to seeing you at the Australian Dementia Forum 2021.

Prof Chris Rowe

Director Australian Dementia Network
Convenor

Organising Committee

Convenor

Prof. Christopher Rowe MD FRACP FAANMS, Director, Australian Dementia Network, University of Melbourne; Director, Molecular Imaging Research, Austin Health; NHMRC Practitioner Fellow

Organising Committee Members

A/Prof. Lyndsey Collins-Praino, Acting Head, Discipline of Anatomy and Pathology, Adelaide Medical School, University of Adelaide; Head, Cognition, Ageing and Neurodegenerative Disease Laboratory, Adelaide Medical School, University of Adelaide.

Dr Mitchell Goldsworthy PhD, Head of Lifespan Human Neurophysiology Group, Adelaide Medical School, University of Adelaide; Hopwood Centre for Neurobiology, South Australian Health and Medical Research Institute; ARC DECRA Research Fellow.

Dr Lisa Kalisch Ellett B Pharm PhD, Senior Research Fellow, Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia.

A/Prof Hannah Keage PhD, University of South Australia; NHMRC Dementia Research Leadership Fellow.

A/Prof. Michael Lardelli PhD, Alzheimer's Disease Genetics Laboratory, University of Adelaide; Secretary, Australasian Neuroscience Society.

A/Prof Kate Laver, BAppSc(OT), MClinRehab, PhD, GCertImpSci, ARC Discovery Early Career Research Fellow, Flinders University.

Associate Professor Tobias Loetscher, Boosting Dementia Research Leadership Fellowship, University of South Australia.

Professor Paul Maruff, ABIL Research Group, The Florey Institute, The University of Melbourne.

Colin L Masters MD, Professor of Dementia Research, Florey Institute and The University of Melbourne.

Maree McCabe, Chief Executive Officer, Dementia Australia.

Prof. Sharon Naismith, MAPS, CCN. NHMRC Dementia Leadership Fellow, University of Sydney; Director, Healthy Brain Ageing Program, Brain and Mind Centre; Chief Investigator, Centre of Research Excellence to Optimise Sleep in Brain Ageing and Neurodegeneration; Lead, Australian Dementia Network Memory Clinics Initiative.

Assoc.Prof. Tuan Anh Nguyen BPharm. MPharm. PhD. Principal Research Fellow, National Ageing Research Institute and Swinburne University of Technology; NHMRC-ARC Dementia Research Development Fellow.

Ann Pietsch, RN, Midwife, BA Applied Science, person living with dementia, member of Dementia Australia Advisory Committee (DAAC), member of Dementia Australia Research Foundation (DARF) – Scientific Panel, member of National Older Person Reference Group (OPAN)

Timothy Pietsch, BMus, Grad Dip Comp Stud, carer of person living with dementia.

Dr Emily Reeve, BPharm(Hons) PhD, Senior Research Fellow and Senior Lecturer in Pharmacy Practice; Quality Use of Medicines and Pharmacy Research Centre, UniSA: Clinical and Health Sciences, University of South Australia

Dr Timothy Sargeant PhD, Head of Lysosomal Health in Ageing, Hopwood Centre for Neurobiology, South Australian Health and Medical Research Institute.

Dr Janet Sluggett PhD, Senior Research Fellow (NHMRC Early Career Fellow), UniSA Allied Health and Human Performance, University of South Australia and Affiliate Postdoctoral Researcher, Registry of Senior Australians, South Australian Health and Medical Research Institute.

Dr Ashleigh Smith PhD, Senior Lecturer (Exercise Physiology), Alliance for Research in Exercise, Nutrition and Activity (ARENA) Research Centre, Allied Health and Human Performance, University of South Australia.

Heads of stream

- **Prof Chris Rowe** – Program Chair
- **Prof Colin Masters** – Head of Discovery and Diagnosis stream
- **Prof Ralph Martins** – Head of Treatment stream
- **Prof Sharon Naismith** – Head of Prevention stream
- **Ms Maree McCabe** – Head of Care stream

Keynote Speakers

Plenary Session 1

Plenary Session 1: Monday 31 May, 09:50 (AEST)

Challenges in Implementing Innovative Programs in Long Term Care: Examples from Pragmatic Randomized Trials

Prof Vincent Mor, *Brown University School of Public Health, Rhode Island, USA*

Quality Improvement Initiatives in health care systems are routinely introduced in settings as diverse as ICUs and nursing homes. However, without a well constructed control group, it is difficult to assess the impact of such innovations. Multi-site, pragmatic randomized clinical trials embedded in health care systems make it possible to assess differences in outcomes but raise other challenges. Many interventions are efficacious when introduced by researchers in controlled circumstances but then are difficult to replicate when introduced within health care systems. Nowhere is this more true than in the case of nursing homes serving many persons living with dementia being cared for by staff with high rates of turnover and minimal training. This presentation discusses the challenges of implementing innovative programs designed to meet the needs of nursing home residents living with dementia through different examples drawn from the authors' own research program.

Plenary Session 2

Plenary Session 2: Monday 31 May 10:53 (AEST)

What's new in the pathology of dementia?

Prof Glenda Halliday, *Brain and Mind Centre and Faculty of Medicine and Health School of Medical Sciences, University of Sydney, Australia*

Until recently, it was thought that there were three main types of dementia pathologies, with most people having Alzheimer's disease (AD) with or without vascular disease, followed by Lewy body dementia (LBD) and then frontotemporal dementia (FTD). In the past few years, the diagnosis of five new and prevalent dementia pathologies (PART, ARTAG, LATE, brain arteriolsclerosis, CTE) and the clarification of rare dementia types has occurred. New biomarkers can now accurately identify AD pathology but multiple additional pathologies drive the cognitive decline observed. There are new diagnostic criteria and new risk genes for LBD, and criteria for prodromal disease. At last, there is a new tau PET ligand that sees all pathological forms of tau, new biomarkers and scales to assist with the diagnosis of FTD, and 18 active clinical trials for FTD. A new rare causative gene for FTD and risk variants for those with language deficits have been identified. So there is a lot that is really new in the pathology of dementia.

Plenary Session 3

Blood based biomarkers for Alzheimer's Disease: getting ready for implementation

Prof Charlotte Teunissen, Department of Clinical Chemistry, VUmc, The Netherlands

Plasma biomarkers have been the holy grail in biomarker research, and recent results show that the come within reach. In the past years, independent studies showed that the proteins reflecting the core AD pathology, amyloid and pTau isoforms, are changed in the blood of AD patients, even in the early stages. These results show a remarkable consistency, across different cohorts but also independent of the analytical method used. The robustness and magnitude of changes allows to prepare for clinical implementation. I will give an overview of the state of the art of these exciting and dynamic developments.

Plenary Session 5

Trials in Presymptomatic Alzheimer's Disease

Prof Paul Aisen MD, USC Alzheimer's Therapeutic Research Institute, California, USA

The ongoing development of accurate biomarkers, including PET, CSF and plasma assays, has enable identification of individuals with AD pathology and mild or no symptoms. Very early intervention trials now test promising therapeutics at the stage of disease to optimize beneficial effects on disease progression.

Plenary Session 4

Can we prevent dementia?

Prof Gill Livingston, University College London, London

Prof Livingston will discuss the evidence that dementia is preventable; the potentially reversible risk factors which have consistent and high quality evidence and other factors in which evidence is building. She will talk about how risks differ between and within populations. She will consider what can be done in terms of changes in policy and what action individuals can take.

Plenary Session 6

What do reactive astrocytes (really) do?

A/Prof Shane Liddelow, Associate Professor, Department of Neuroscience and Physiology, NY University Langone Health

Astrocytes are one of the most abundant cells in the mammalian central nervous system. They are integral to brain and spinal-cord physiology and perform many functions important for normal neuronal development, synapse formation, and proper propagation of action potentials. We still know very little, however, about how these functions change in response to immune attack or during chronic neurodegenerative disease. This presentation will focus on new insights into astrocyte heterogeneity, and give insights into novel substates of reactive astrocytes that can be targeted during a range of neurodegenerative diseases.

Plenary Session 7

Dementia in Aboriginal and Torres Strait Island Communities: A journey through health, ageing and dementia in the Torres Strait and Cape York

Dr. Eddy Strivens, Clinical Director, Older Persons Sub-Acute and Rehabilitation (OPSAR)

In Australia, Aboriginal and Torres Strait Islanders peoples aged 45 and over have three to five times higher rates of dementia than the wider community and with the older population growing, with the proportion aged over 65 years expected to double in the next decade, dementia rates are set to increase dramatically in these communities. Older Aboriginal and Torres Strait Islanders play a crucial role in the health of their communities including holding the cultural rights and responsibilities for maintaining connections to Country, caring for extended family members, and providing leadership and support in their families and within communities. Addressing the high rates of dementia within these communities not only improves the life of individuals and their communities but also reduces burden on local health care and the economy. The Health Ageing Research Team (HART) in Cairns, Far North Queensland, has been working in partnership with regional and remote communities in the Torres Strait and Cape York for the last twenty years to help address issues around dementia and other associated disease of ageing, including partnerships with other research groups across Australia New Zealand and beyond. From an initial start of looking at awareness of dementia and ageing, through the use of culturally appropriate assessment tools and the prevalence of dementia in the Torres Strait and now the development of community developed models of healthy ageing and targeted ways of reducing dementia risk in these communities, HART has striven to blend community driven research questions with ongoing clinical service provision within the Aboriginal and Torres Strait Islander communities of Far North Queensland.

Plenary Session 8

The neuropsychiatric aspects of neurodegenerative disorders

Prof Dag Aarsland, King's College London, London

Alzheimer's, Parkinson's and other neurodegenerative disorders, although usually defined by their dominant cognitive or motor symptoms, very often include a spectrum of neuropsychiatric symptom. Typical symptoms are depression, hallucinations, and apathy, which are often causing great distress to patients and their families. This presentation will review the typical features, their diagnosis and management.

Virtual Platform

Callout labels on the screenshot:

- Export your notes & connections directly to our email
- Live Support
- FAQ's
- Your Profile Settings
- Click on each day to view the day's program
- Scroll to view full program
- Virtual Exhibition, Meeting Hub - Accessible anytime
- When sessions open a JOIN button will appear
- Save your favourites by clicking on the star icon
- Presenter Gallery
- Session Preview

Screenshot content:

ADF 2021 VIRTUAL EVENT PLATFORM

Australian Dementia Network

31 May – 1 June

Australian Dementia Forum 2021

LIVE SUPPORT   DND   EXPORT   HELP   ES

Australian Dementia Network
REGISTRY. CLINICS. TRIALS.

Australian Dementia Forum 2021
Dementia Research: Discovery, Innovation, Translation.

31 May – 1 June

No further events today

Filter   Advanced

TODAY   MAY 31   JUN 1

9:00am

Plenary Session 1 – Challenges in Implementing Innovative Programs in Long Term Care: Examples from Pragmatic Randomized Trials, Prof Vincent Mor, Brown University School of Public Health, Rhode Island, USA
9:21am – 9:53am

Plenary 1 LIVE Q&A
9:53am – 10:08am

10:00am

Morning Break 1 – Day 1
10:08am – 10:23am

Plenary Session 2, What's new in the pathology of dementia, Prof Glenda Halliday, Brain and Mind Centre and Faculty of Medicine and Health School of Medical Sciences, University of Sydney, Australia

Virtual Exhibition   Visit

Meeting Hub   View

Presenter Gallery
Poster Gallery

MORE INFORMATION
Click on an event to learn more about it

OnAIR
by EventsAIR

Items: 819   All folders are up to date.   Connected to: Microsoft Exchange

Search for anything   14°C Alert   ENG   10:59 AM 25/05/2021

Virtual Platform

The ADF 2021 conference will be delivered via the EventsAir Virtual Platform.

You will receive your unique login the week prior to the conference. Use this to access the conference program from your personal device.

Program Timeline

When you log into the platform, the full conference program listing all oral presentations and times will be displayed on the Program Timeline. A red line will move down the screen as the event proceeds, indicating the time sessions goes live. Scroll the timeline and save your 'favourites' by clicking on the star adjacent the sessions you don't want to miss – a handy tool to plan your day.

You will need to select each session you want to attend by clicking the View/Jvoin button to the right of the presentation on the timeline. Breaks are scheduled throughout the program where you will have time to explore all areas of the virtual platform, including the Poster Gallery, Exhibition, and Meeting Hub.

Poster Presentations are available to view at any time when logged in to the virtual platform. These can be accessed via the Poster Gallery located on the right-hand side of the screen. Posters are listed in alphabetical order and can be searched by author, title, number or topic using the advanced search function. Some Poster Presenters have also provided a video to accompany their Poster. Watch them, ask questions and leave feedback for the Poster Presenters via text in the discussion forum provided.

Log in details:

Your unique log in will be emailed to you the week prior to the conference. Please note your login is personalised and cannot be shared.

Taking the time to log into the platform and setting up your profile ahead of the live event will save you time when logging in on the day.

Setting up your profile is easy, simply follow the prompts and when complete, you are ready to explore the platform's features. Familiarise yourself with the virtual timeline, star the sessions you wish to watch, read more about the presentations, view the virtual exhibition and poster gallery and much more.

Equipment and Browser Information

For the best user experience a laptop or PC is recommended to access the virtual conference, and Google Chrome is the recommended browser. Avoid having additional browser tabs open at the same time.

Attendee Participation

The virtual platform has many features to maximise the opportunities for attendees to participate in the proceedings.

Live Q & A

Each plenary and concurrent session block will conclude with a live Q&A with presenters who participated in the session available to answer questions from attendees. As attendees watch the presentations, questions can be added to the Q & A chat box via text. During the live Q&A panel, submitted questions will be asked, with the panel providing live responses. In addition, attendees and presenters will be able to participate in a discussion forum throughout the session.

Meeting Hub

The meeting hub is where you can meet and interact with your colleagues. See who has logged in and is attending the event, make new connections and engage in a live one-on-one video chat.

Use the left-hand menu to find another attendee and invite them to become a "Connection". Once the connection invitation has been accepted, you'll be able to interact with that attendee in many different ways, including Live Chat sessions and one-on-one video Meetings.

Virtual Exhibition

Without the support of our Sponsors, this event would not be possible. Please take the time to visit their virtual exhibition booth or make connections with them while in the meeting hub. Each virtual booth has videos, handouts and contact information available to you to explore and download.

Exhibitors are encouraged to staff their stand 30 minutes prior to the beginning of each day's program and during all scheduled breaks. You can schedule a meeting and have live one-on-one chats.
If there is no-one there, make sure you grab their contact details and send them an email! They would be happy to hear from you!

Virtual Networking

A virtual networking session for delegates is scheduled at the end of proceedings on Monday 31 May. Join the online networking function to engage and chat with your peers. A rotation of short 10 minute sessions with four attendees at a time will keep conversation dynamic and energetic.

Tips to make the most of short conversations:

- Briefly introduce yourself
- Speak clearly
- Ask direct questions
- Discuss your favourite presentation

On-demand access

Delegates will have on-demand access to the full conference program including the pre-recorded presentations, poster presentations and recorded live Q & A Panel Discussions for up to two months after the conference.

Technical support

Live technical support is immediately accessible via the support icon (see image on page 14 & 15) at the top right of the online conference portal. Log your query in the live support chat box and a team member will respond as quickly as possible.

If you are unable to log into the virtual platform, help is available through contacting **ADF2021@eventsudio.com.au**.

Presenter and Chair Instructions

Step 1. Click on your unique link to access the Virtual Platform

**Step 2.** Find your session on the Virtual Timeline

Step 3. Find the Live Q&A banner at the end of your session block (this is a darker shade) and select join/view

Step 4. Click join Green Room

Step 5. Set you camera and audio

Step 6. Say hello the tech/ operator in the green room and follow their instructions.

Step 7. Familiarize yourself with the bottom bar and find presenter chat – this is where questions will be pasted in from co-chairs, collected from the earlier sessions.

Logging in & preferred browser

Your unique log in will be sent you the week prior to the live event. Please take the time to log in, set up your profile and familiarise yourself with the virtual platform. This will save you time when logging in on the day as this may take you 15 minutes to complete.

The EventsAir Virtual Platform works best using Google Chrome as your website browser. For More Information including the Speaker Briefing Video, click here.

For More Information including the Speaker Briefing Video , click here.

ADF Speaker Briefing Recording

Live Q & A

Live Q & A Questions will be submitted by attendees via the text Q&A function in the portal while the prerecorded presentations play live. Co-chairs will assist Chairs in gathering the best and highest ranked questions ready for the live discussion led by the session Chair by copying questions from the pre-recorded live Q& A chat box and pasting the questions into the presenter chat box in the green room.

All Presenters will join in the panel-style live Q&A scheduled at the conclusion of the session. Questions raised by participants will be asked live by the session Chair during this Q & A session to encourage engaging conversations. Presenters and Chairs are asked to log into their live Q & A session via their unique presenter link 20 minutes prior to the scheduled time. An AV Tech will be present online and ensure you are ready to go live. At the conclusion of the session, Presenters and Chairs can return to the timeline and participate in the conference as usual.

What device should I use to do my live Q & A?

We recommend you use a laptop or desktop computer with a webcam and headset for your participation in the live Q&A. This will provide the best results and ease of use.

We encourage all presenters to go back into their session and answer any questions posted by participants that were not answered during the live Q&A. These will be added and remain on the virtual platform until 31 July.

What if I have camera or audio problems?

Reset/review your internet browser permissions for your camera and microphone. For example, in Chrome, you can click on the small lock icon to the left of the URL to check on these settings. Make sure you know where to find these settings before the first day of the convention.

Who do I contact for support during the live event?

Our Live Event Support Team is online and available for you at any time during the live event. If you have any questions or need technical assistance, click on the red Live Support icon in the top right of the screen.

Live support will be available throughout the conference opening hours and will include dedicated IT/AV support.

Poster Presenters

Attendees will be able to access Poster Presentations as soon as they log into the portal.

Attendees can view your Poster PDF / Video, add comments and ask questions to the discussion forum via text. Please make sure you check back into your Poster Presentation to answer any queries that arise. Delegates will be encouraged to view posters during the scheduled breaks throughout the conference.

In addition, Poster Presentations will made available for up to 2 months post event and viewed on demand at delegate's convenience.

Click here to download program

Frequently asked questions

Can more than one person use the conference login details?
No. Each registration is just for a single person, and your unique login is for your personal use only. Content cannot be exported out of the platform for a shared experience.

How do I setup my profile?
Upon logging in to the virtual platform, your Profile/Account tab will appear - we encourage you to add a photo, short biography, and links to your social media accounts. You can edit your profile at any time.

Your profile tab is also where you can restrict/allow what is seen in the Meeting Hub/online delegate list.

What days/times are the sessions?
The dates are Monday 31 May and Tuesday 1 June 2021.

The time zone is based on Australian Eastern Standard Time (UTC +10).

Please view the full program here for times and session details.

When will I receive my unique log in for attending the event?
Your personal login is attached in the email you received this week, together with this Handbook. Make sure that the email address associated with your registration is accurate and up to date so that there is no delay in receiving our communications.

Will sessions be pre-recorded or live?
Most presentations will be pre-recorded but you have the opportunity to interact with presenters via the live Q&A.

If the speaker is not available, we encourage you to post your question anyway. Speakers will record answers to those questions not raised during the live Q&A and post online.

How do I join a session?
The Program Timeline shows all of the sessions, including the networking event, during and after the program. To join a session or a talk, simply click on the View/Join button and you will be directed into the session page.

How do I make sure I don't miss a particular session/talk?
In the Program timeline, every Session/talk will have their own 'favourites' star icon – simply click on this icon and you will have it stored as your favourites. To access your favourite sessions/talks, simply click on the favourites icon located in the right hand corner below the time counter.

Will I be able to jump from session to session during the conference?
Yes. But you will need to leave a session, and click back to the program timeline, before you can enter another session.

Will sessions be recorded and available after the conference?
Yes, all presentations will be made available after the meeting for up to 2 months until 31 July 2021. This also includes access to the virtual exhibition, Poster Presentations and all handouts including abstracts.

Will attendees be able to ask questions during sessions?
Yes, via the Q&A box in the session.

Every oral presentation will include a Q&A segment. Delegates will have the ability to enter questions into the "Q&A" box and also vote on submitted questions to assist the chair in selecting questions to ask. At the end of the presentation, the chairperson will read the questions to the speaker, who will then respond live (if available). If the speaker is not available, questions can still be entered in the Q&A box which will be answered by the speaker after the session and made available on demand in the Answered area of the Q&A box.

For Poster Presentations, delegates will be able to interact and ask questions via the discussion forum box in the Presenter/Poster Gallery.

How can I access Poster Presentations?
The Poster Gallery will be available for registered delegates prior, during and after the meeting until 31 July 2021.

In the Poster Gallery you will be able to browse and search for posters that interest you. You can then click on the Poster to find out more information and to view the Poster.

Will we have access to abstracts?
Yes. Abstracts will be included as 'handouts' in all sessions including Poster sessions. The Poster Gallery will also include the Poster in PDF format.

A full abstract book including the Oral and Posters Abstracts will be available to download by clicking on the link at the top of the Virtual Timeline.

What is the Virtual Exhibition?
The Virtual Exhibition is our 'exhibition hall' where you can view and meet our Sponsors.

The virtual exhibition can be viewed anytime over the two days of the conference and after the meeting until 31 July 2021.

Delegates can search and browse the exhibitors information, and when clicked into the exhibitors booth, delegates can view profiles, download handouts, view videos, click on website links, as well as take notes and export these to their email. Delegates can also connect via the Meeting Hub with exhibitors.

If Sponsors are available during the event, delegates can also meet one-on-one with exhibitors by requesting a meeting, with live video chat; exhibitors can also share their screen to present information to delegates. Delegates can also record the meeting which can be exported to their email.

What is the Meeting Hub?
The Meeting Hub allows you to connect and communicate with other delegates. You can search for delegates, and connect with them by clicking on the Connect button. Once the other delegate accepts your request, you can choose to interact with your connection by starting a live chat or live video call. You can also schedule to meet at a future time, send messages and take notes. Contact information for all attendees you have connected with is included when you export your contacts.

When you first enter the conference portal delegates will be asked to update their profile, and this includes 'privacy' and 'meeting hub' options where you can choose what contact information you wish to share.

Australian
Dementia Network

REGISTRY. CLINICS. TRIALS.

www.australiandementianetwork.org.au